AI assistant
KALA BIO, Inc. — Director's Dealing 2025
Dec 22, 2025
35091_dirs_2025-12-22_61fe1310-284e-48c5-bd91-0ded6c7e8ce8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: KALA BIO, Inc. (KALA)
CIK: 0001479419
Period of Report: 2025-12-18
Reporting Person: Lazar David E. (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-18 | Convertible Loan | $1.017 | J | 368614 | Disposed | Common Stock (368614) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 0 | Direct |
Footnotes
F1: No shares of common stock are beneficially owned.
F2: Not applicable.
F3: On November 9, 2025, the Reporting Person, as "Lender", entered into a Convertible Loan Agreement (the "Agreement") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the "Conversion Price" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash.